What is the current price and trading status of IHL.AX stock?

IHL.AX stock is trading pre-market at **A$0.041** on 10 Feb 2026, down **-10.87%** with **61,360,016** shares traded. The stock is listed on the ASX and is experiencing heavy intraday volume that increases short-term volatility.

How does Incannex’s valuation look compared to the healthcare sector?

IHL.AX stock shows a price-to-book of **0.75**, below the Healthcare sector PB near **5.07**, suggesting low asset multiple. However, earnings are negative (EPS **-1.30**) and the PE is negative, so valuation must be viewed against clinical development risk.

What catalysts should investors watch for IHL.AX stock?

Watch clinical trial readouts (notably IHL-42X Phase 2/3), partnership or licensing deals, and funding announcements. These events tend to trigger volume spikes and large price moves for IHL.AX stock given its micro-cap status.

What is Meyka AI’s forecast and rating for IHL.AX stock?

Meyka AI rates IHL.AX **65 (Grade B) – HOLD** and its forecast model projects a **12‑month target of A$0.075**, implying **+82.93%** upside from **A$0.041**. Forecasts are model-based projections and not guarantees.

AU Stocks

IHL.AX Incannex ASX pre-market 10 Feb 2026: A$0.041 on heavy volume

ByHuzaifa Zahoor February 10, 2026February 10, 2026

IHL.AX stock is trading at A$0.041 pre-market on 10 Feb 2026 after a -10.87% one-day move on very heavy 61,360,016 shares. The ASX-listed Incannex Healthcare Limited (IHL.AX) shows extreme intraday interest compared with its 6,427,691.00 average volume, signalling speculative trading ahead of clinical and funding news. At A$14,255,927.00 market cap the company remains a micro-cap biotech in Australia’s healthcare sector, and the pre-market action is the key short-term driver for traders watching product trial milestones and cash runway metrics.